跳至主要内容
临床试验/NCT04861896
NCT04861896已完成不适用

An e-Health Intervention to Improve Symptom Burden and Health-Related Quality of Life Among Hispanic Women Completing Active Treatment for Breast Cancer

Northwestern University2 个研究点 分布在 1 个国家目标入组 58 人开始时间: 2021年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
58
试验地点
2
主要终点
Demand of My Guide: Retention Rate

研究概览

简要总结

The purpose of this study is to examine the feasibility and preliminary efficacy of a psychosocial eHealth intervention designed to improve hormone therapy adherence among Hispanic/Latinx women with breast cancer. Our proposed secondary outcomes are health-related quality of life and self-efficacy in managing hormone therapy side effects.

The intervention components include breast cancer knowledge, hormone/endocrine therapy knowledge, stress awareness and management, social support, and enhanced communication and intimacy skills. The intervention will be delivered via a Smartphone application over a 12-week period.

All participants will receive the intervention application (described below). Aside from using the Smartphone application for the recommended 12 weeks, participation in this study includes three assessments: baseline (at the beginning of the research study), 6-week follow-up, and 12-week follow-up.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Diagnosis of breast cancer, non-metastatic, stage 0-III (A, B, or C)
  • Receiving or received endocrine/hormone therapy within the last 3 years (36 months)
  • At least 18 years of age
  • Able to speak and read English or Spanish
  • Able to provide informed consent
  • Self-identify Hispanic/Latina ethnicity

排除标准

  • Stage IV or metastatic
  • Visual, hearing, voice, or motor impairment that would prevent completion of study procedures
  • Diagnosis of an unmanaged psychotic disorder, bipolar disorder, dissociative disorder, or other diagnoses for which participation in this trial is either inappropriate or dangerous - this includes patients who have a life-threatening illness (e.g., end-stage kidney disease) or diagnosis of a chronic disease that is associated with a major functional impairment (e.g., fibromyalgia)
  • Illicit substance or alcohol dependence
  • Suicidal ideation, plan, intent
  • Alzheimer's, dementia, or history of stroke
  • Scheduled reconstruction surgery within 1 month of any study procedures or involvement.

结局指标

主要结局

Demand of My Guide: Retention Rate

时间窗: 12 weeks

Another way we assess demand of the My Guide application is through participant retention. Based on previous psychosocial and behavioral studies in oncology, an 70% retention rate is considered an adequate level of demand.

Participant use of My Guide: Number of Login's

时间窗: 12 weeks

We assess participant use of the My Guide application by examining the number of participant logins to the web-based application.

Acceptability of My Guide: Learnability

时间窗: T3 (immediately following 12 week intervention)

To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

Acceptability of My Guide: Usability

时间窗: T3 (immediately following 12 week intervention)

To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

Demand of My Guide: Recruitment Rate

时间窗: 12 weeks

We assess demand of the My Guide application through study recruitment. Based on previous psychosocial and behavioral studies in oncology, an 70% recruitment rate is considered an adequate level of demand.

Participant use of My Guide: Duration of Usage

时间窗: 12 weeks

We assess participant use of the My Guide application by examining the duration participant time spent on the website. Based on previous psychosocial and behavioral studies in oncology, an average of 8 hours of use is considered an adequate level of engagement.

Participant use of My Guide: Content Accessed

时间窗: 12 weeks

We assess participant use of the My Guide application by examining the type of content accessed by participants on the website.

Change in Medication adherence will be assessed primarily with the Adherence to Refills and Medication Scale (ARMS).

时间窗: T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention)

The ARMS (Adherence to Refills and Medications Scale) survey is a previously validated patient-report measure of barriers to medication adherence and adherence-related behavior.

Acceptability of My Guide: Satisfaction

时间窗: T3 (immediately following 12 week intervention)

To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

Acceptability of My Guide: Usefulness

时间窗: T3 (immediately following 12 week intervention)

To assess acceptability, all participants are asked to complete an exit interview on My Guide. This interview assesses usefulness, satisfaction, learnability and usability of the application. This exit interview was synthesized from validated measures assessing eHealth intervention acceptability, and was adapted for our study to better fit our target population and our application design. Above average scores on the questionnaire are considered acceptable. The questionnaire is administered over the phone immediately following the 12 week intervention.

次要结局

  • Change in Patient Self-Efficacy in managing side effects is measured using the PROMIS Self Efficacy for Managing Symptoms(T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention))
  • Change in Health Related Quality of Life will be evaluated with The Functional Assessment of Cancer Therapy (FACT-G7)(T1 (prior to starting intervention), T2 (6 weeks into intervention), T3 (immediately following 12 week intervention))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Betina Yanez

Associate Professor

Northwestern University

研究点 (2)

Loading locations...

相似试验